Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
Portfolio Pulse from Vandana Singh
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) announced new preclinical data for its novel oral ketamine analog, Ketamir-2, which shows potential in treating neurological and neuropsychiatric disorders. The data reveals Ketamir-2's selective inhibition of the NMDA receptor and favorable safety profile. MIRA's stock surged 38.8% following the announcement.
July 25, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' new preclinical data for Ketamir-2 shows selective inhibition of the NMDA receptor and a favorable safety profile, boosting investor confidence. The stock surged 38.8% on the news.
The announcement of promising preclinical data for Ketamir-2, showing selective inhibition of the NMDA receptor and a favorable safety profile, has significantly boosted investor confidence. This is reflected in the 38.8% surge in MIRA's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100